Published in Biotechniques on January 01, 1993
New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol (2003) 8.25
Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins. J Virol (1998) 5.05
Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1. PLoS Pathog (2009) 4.04
Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection. J Virol (1997) 3.79
Rapid detection and quantification of members of the archaeal community by quantitative PCR using fluorogenic probes. Appl Environ Microbiol (2000) 3.29
Comparison of the ABI 7700 system (TaqMan) and competitive PCR for quantification of IS6110 DNA in sputum during treatment of tuberculosis. J Clin Microbiol (1998) 2.91
Heritable susceptibility to severe Borrelia burgdorferi-induced arthritis is dominant and is associated with persistence of large numbers of spirochetes in tissues. Infect Immun (1994) 2.81
Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV. J Virol (2000) 2.65
Activation of virus replication after vaccination of HIV-1-infected individuals. J Exp Med (1995) 2.26
Relevance of nucleic acid amplification techniques for diagnosis of respiratory tract infections in the clinical laboratory. Clin Microbiol Rev (1997) 2.11
Biological variation and quality control of plasma human immunodeficiency virus type 1 RNA quantitation by reverse transcriptase polymerase chain reaction. J Clin Microbiol (1993) 1.94
Evidence that the human foamy virus genome is DNA. J Virol (1999) 1.85
HIV does not replicate in naive CD4 T cells stimulated with CD3/CD28. J Clin Invest (1997) 1.83
Cell-free human immunodeficiency virus type 1 in breast milk. J Infect Dis (1998) 1.74
Quantitative competitive reverse transcription-PCR for quantification of dengue virus RNA. J Clin Microbiol (2000) 1.64
Dominant-negative inhibitors of EBNA-1 of Epstein-Barr virus. J Virol (1997) 1.59
A virion concentration method for detection of human enteric viruses in oysters by PCR and oligoprobe hybridization. Appl Environ Microbiol (1996) 1.49
Quantification of Nitrosomonas oligotropha-like ammonia-oxidizing bacteria and Nitrospira spp. from full-scale wastewater treatment plants by competitive PCR. Appl Environ Microbiol (2002) 1.47
Unique pathology in simian immunodeficiency virus-infected rapid progressor macaques is consistent with a pathogenesis distinct from that of classical AIDS. J Virol (2007) 1.44
Detection of Clostridium proteoclasticum and closely related strains in the rumen by competitive PCR. Appl Environ Microbiol (1998) 1.37
Automated quantitative determination of hepatitis C virus viremia by reverse transcription-PCR. J Clin Microbiol (1994) 1.29
Maternal plasma human immunodeficiency virus type 1 RNA level: a determinant and projected threshold for mother-to-child transmission. Proc Natl Acad Sci U S A (1995) 1.25
Longitudinal assessment of feline immunodeficiency virus kinetics in plasma by use of a quantitative competitive reverse transcriptase PCR. J Virol (1995) 1.23
Quantitative molecular monitoring of human immunodeficiency virus type 1 activity during therapy with specific antiretroviral compounds. J Clin Microbiol (1995) 1.16
Neurokinin-1 receptor expression in inflammatory bowel disease: molecular quantitation and localisation. Gut (2000) 1.15
Frequency of pilin antigenic variation in Neisseria gonorrhoeae. J Bacteriol (1998) 1.12
Quantitation of hepatitis C virus genome molecules in plasma samples. J Clin Microbiol (1994) 1.12
Development of catechol 2,3-dioxygenase-specific primers for monitoring bioremediation by competitive quantitative PCR. Appl Environ Microbiol (2000) 1.09
Localised sequence regions possessing high melting temperatures prevent the amplification of a DNA mimic in competitive PCR. Nucleic Acids Res (1998) 1.06
Dynamics of molecular parameters of human immunodeficiency virus type 1 activity in vivo. J Virol (1994) 1.04
Applications of competitor RNA in diagnostic reverse transcription-PCR. J Clin Microbiol (2003) 1.02
Clinical use of quantitative molecular methods in studying human immunodeficiency virus type 1 infection. Clin Microbiol Rev (1996) 1.02
Interleukin-4-dependent immunoglobulin G1 isotype switch in the presence of a polarized antigen-specific Th1-cell response to the trypanosome variant surface glycoprotein. Infect Immun (1998) 1.01
Quantitative measure of small-subunit rRNA gene sequences of the kingdom korarchaeota Appl Environ Microbiol (1998) 1.00
Correlations of Y chromosome microchimerism with disease activity in patients with SLE: analysis of preliminary data. Ann Rheum Dis (2003) 0.97
Enhancement of feline immunodeficiency virus (FIV) infection after DNA vaccination with the FIV envelope. J Virol (1997) 0.97
An adenovirus-Epstein-Barr virus hybrid vector that stably transforms cultured cells with high efficiency. J Virol (1999) 0.96
Determination of optimal sites of antisense oligonucleotide cleavage within TNFalpha mRNA. Nucleic Acids Res (2001) 0.93
Cytokines and cytokine measurements in a clinical laboratory. Clin Diagn Lab Immunol (1994) 0.93
Plasma viral RNA load predicts disease progression in accelerated feline immunodeficiency virus infection. J Virol (1996) 0.93
Quantitation of human immunodeficiency virus type 1 DNA by two PCR procedures coupled with enzyme-linked oligosorbent assay. J Clin Microbiol (1995) 0.92
Decreased levels of recent thymic emigrants in peripheral blood of simian immunodeficiency virus-infected macaques correlate with alterations within the thymus. J Virol (2002) 0.91
In vivo T-lymphocyte activation and transient reduction of viral replication in macaques infected with simian immunodeficiency virus. J Virol (2001) 0.91
Quantification of hepatitis C virus RNA by competitive amplification of RNA from denatured serum and hybridization on microtiter plates. J Clin Microbiol (1995) 0.90
Impact of alcaligin siderophore utilization on in vivo growth of Bordetella pertussis. Infect Immun (2007) 0.90
Interleukin-16 inhibits human immunodeficiency virus type 1 entry and replication in macrophages and in dendritic cells. J Virol (1999) 0.89
The synthetic immunomodulator murabutide controls human immunodeficiency virus type 1 replication at multiple levels in macrophages and dendritic cells. J Virol (2000) 0.89
Antiviral therapy reduces viral burden but does not prevent thymic involution in young cats infected with feline immunodeficiency virus. Antimicrob Agents Chemother (2000) 0.89
Development of a quantitative competitive PCR assay for detection and quantification of Escherichia coli O157:H7 cells. Appl Environ Microbiol (2001) 0.88
Analysis of the gene family encoding lipases in Candida rugosa by competitive reverse transcription-PCR. Appl Environ Microbiol (1999) 0.87
Efficient isolation of human immunodeficiency virus type 1 RNA from cervical swabs. J Clin Microbiol (1998) 0.86
Type 1 and type 2 cytokine gene expression by viral gp135 surface protein-activated T lymphocytes in caprine arthritis-encephalitis lentivirus infection. J Virol (1997) 0.83
Selective regulation of human immunodeficiency virus-infected CD4(+) lymphocytes by a synthetic immunomodulator leads to potent virus suppression in vitro and in hu-PBL-SCID mice. J Virol (2001) 0.81
Clinical evaluation of an in-house reverse transcription-competitive PCR for quantitation of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol (1999) 0.80
Use of multiple competitors for quantification of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol (1998) 0.79
Monocytes of individual human subjects display heterogeneous bacterial uptake and antilisterial activity. Infect Immun (1996) 0.78
Quantification of mRNA expression by competitive PCR using non-homologous competitors containing a shifted restriction site. Nucleic Acids Res (2001) 0.78
Membrane-associated and soluble granulocyte/macrophage-colony-stimulating factor receptor alpha subunits are independently regulated in HL-60 cells. Proc Natl Acad Sci U S A (1995) 0.78
Infection of SK-N-MC cells, a CD4-negative neuroblastoma cell line, with primary human immunodeficiency virus type 1 isolates. J Virol (1996) 0.78
Retrotransposition of nonviral RNAs in an avian packaging cell line. J Virol (1998) 0.77
Quantification of siRNA using competitive qPCR. Nucleic Acids Res (2008) 0.77
Fetal outcome in murine Lyme disease. Infect Immun (1995) 0.76
Correction of a carboxyl terminal simian immunodeficiency virus Nef frameshift mutation restores virus replication in macaques. Virology (2010) 0.75
Viral dynamics in human immunodeficiency virus type 1 infection. Nature (1995) 28.54
High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science (1993) 12.22
pH-independent HIV entry into CD4-positive T cells via virus envelope fusion to the plasma membrane. Cell (1987) 9.29
British Hypertension Society guidelines for hypertension management 1999: summary. BMJ (1999) 8.80
Induction of CD4-dependent cell fusion by the HTLV-III/LAV envelope glycoprotein. Nature (1986) 8.36
The Regenstrief Medical Record System: a quarter century experience. Int J Med Inform (1999) 7.68
Guidelines for management of hypertension: report of the third working party of the British Hypertension Society. J Hum Hypertens (1999) 6.74
Evaluation of nurse triage in a British accident and emergency department. BMJ (1992) 6.71
Targeted disruption of the three Rb-related genes leads to loss of G(1) control and immortalization. Genes Dev (2000) 5.80
AIDS retrovirus induced cytopathology: giant cell formation and involvement of CD4 antigen. Science (1986) 5.58
Molecular cloning and disease association of hepatitis G virus: a transfusion-transmissible agent. Science (1996) 5.55
Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins. J Virol (1998) 5.05
Isolation of a cDNA from the virus responsible for enterically transmitted non-A, non-B hepatitis. Science (1990) 4.95
Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum (1998) 4.37
MAOA, maltreatment, and gene-environment interaction predicting children's mental health: new evidence and a meta-analysis. Mol Psychiatry (2006) 4.16
Estimates of general practitioner workload: a review. J R Coll Gen Pract (1989) 4.04
HIV infection among youth in a South African mining town is associated with herpes simplex virus-2 seropositivity and sexual behaviour. AIDS (2001) 3.92
Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection. J Virol (1997) 3.79
Plasma SIV RNA viral load determination by real-time quantification of product generation in reverse transcriptase-polymerase chain reaction. AIDS Res Hum Retroviruses (1998) 3.40
Conflicts regarding decisions to limit treatment: a differential diagnosis. JAMA (2000) 3.27
Vpx is required for dissemination and pathogenesis of SIV(SM) PBj: evidence of macrophage-dependent viral amplification. Nat Med (1998) 3.19
Identification of highly attenuated mutants of simian immunodeficiency virus. J Virol (1998) 2.94
Quiescence, cycling, and turnover in the primitive hematopoietic stem cell compartment. Exp Hematol (1997) 2.92
Funding of long term care for older people needs to be publicly debated. BMJ (2000) 2.90
Assessment of hepatitis C viremia using molecular amplification technologies: correlations and clinical implications. Ann Intern Med (1995) 2.83
Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nat Med (1999) 2.77
Potential utility of empirical tuberculosis treatment for HIV-infected patients with advanced immunodeficiency in high TB-HIV burden settings. Int J Tuberc Lung Dis (2011) 2.77
Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum (2002) 2.75
JNK2 and IKKbeta are required for activating the innate response to viral infection. Immunity (1999) 2.74
Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation. J Virol (1999) 2.69
Protection by live, attenuated simian immunodeficiency virus against heterologous challenge. J Virol (1999) 2.65
The reproducibility of central aortic blood pressure measurements in healthy subjects using applanation tonometry and sphygmocardiography. J Hum Hypertens (1999) 2.48
Interferon-gamma release assays do not identify more children with active tuberculosis than the tuberculin skin test. Eur Respir J (2009) 2.44
Risk factors for HIV infection among women in Carletonville, South Africa: migration, demography and sexually transmitted diseases. Int J STD AIDS (2003) 2.40
Exposure to violence during childhood is associated with telomere erosion from 5 to 10 years of age: a longitudinal study. Mol Psychiatry (2012) 2.37
Angiotensin II antagonists for hypertension: are there differences in efficacy? Am J Hypertens (2000) 2.35
Cooperative interactions between the central spindle and the contractile ring during Drosophila cytokinesis. Genes Dev (1998) 2.32
The initial effects on workload and outcome of a public education campaign on early diagnosis and treatment of malignant melanoma in Leicestershire. Br J Dermatol (1990) 2.22
Better blood pressure control: how to combine drugs. J Hum Hypertens (2003) 2.19
Pathogenesis of post-traumatic syringomyelia. Br J Neurosurg (1992) 2.12
High viral load in the cerebrospinal fluid and brain correlates with severity of simian immunodeficiency virus encephalitis. J Virol (1999) 2.08
Variations in the accuracy of obstetric procedures and diagnoses on birth records in Washington State, 1989. Am J Epidemiol (1993) 2.07
Chemical inactivation of retroviral infectivity by targeting nucleocapsid protein zinc fingers: a candidate SIV vaccine. AIDS Res Hum Retroviruses (1998) 1.97
Is social capital a useful conceptual tool for exploring community level influences on HIV infection? An exploratory case study from South Africa. AIDS Care (2002) 1.93
Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines. J Hypertens (2003) 1.93
Constitutive expression of a gene encoding a polypeptide homologous to biologically active human platelet protein in Rous sarcoma virus-transformed fibroblasts. Proc Natl Acad Sci U S A (1987) 1.90
MHC-I-restricted presentation of HIV-1 virion antigens without viral replication. Nat Med (2001) 1.81
Devaluation of stimuli contingent on choice: evidence for conditioned reinforcement. J Exp Anal Behav (1987) 1.80
Is aqueduct stenosis a result of hydrocephalus? Brain (1973) 1.80
Compromised gastrointestinal integrity in pigtail macaques is associated with increased microbial translocation, immune activation, and IL-17 production in the absence of SIV infection. Mucosal Immunol (2010) 1.78
Targeted therapies in rheumatoid arthritis: the need for action. Rheumatology (Oxford) (1999) 1.78
Molecular cloning and sequencing of cDNAs encoding the entire rat fatty acid synthase. Proc Natl Acad Sci U S A (1989) 1.77
Assessing compliance to antihypertensive medications using computer-based pharmacy records. Med Care (1997) 1.75
Potential for an intervention based on male circumcision in a South African town with high levels of HIV infection. AIDS Care (2003) 1.74
GLQ223: an inhibitor of human immunodeficiency virus replication in acutely and chronically infected cells of lymphocyte and mononuclear phagocyte lineage. Proc Natl Acad Sci U S A (1989) 1.73
Integrin-linked kinase (ILK): a regulator of integrin and growth-factor signalling. Trends Cell Biol (1999) 1.72
Mines, migrancy and HIV in South Africa--managing the epidemic. S Afr Med J (1996) 1.70
Reduction of enzyme levels by propranolol after acute myocardial infarction. Circulation (1978) 1.68
Influence of hypertension, left ventricular hypertrophy, and left ventricular systolic dysfunction on plasma N terminal proBNP. Heart (2000) 1.67
Telomere length in small-for-gestational-age babies. BJOG (2006) 1.66
Management and outcome of posttraumatic syringomyelia. J Neurosurg (1996) 1.66
Aqueduct stenosis. Case review and discussion. J Neurol Neurosurg Psychiatry (1977) 1.65
On the pathogenesis of syringomyelia: a review. J R Soc Med (1980) 1.64
Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity. Mol Psychiatry (2012) 1.63
Tuberculosis prevalence surveys: rationale and cost. Int J Tuberc Lung Dis (2008) 1.63
Loss of mucosal CD103+ DCs and IL-17+ and IL-22+ lymphocytes is associated with mucosal damage in SIV infection. Mucosal Immunol (2012) 1.62
The distending force in the production of "communicating syringomyelia". Lancet (1969) 1.58
Mapping tsetse habitat suitability in the common fly belt of southern Africa using multivariate analysis of climate and remotely sensed vegetation data. Med Vet Entomol (1997) 1.58
The use and misuse of bed-occupancy and waiting-list figures. Lancet (1968) 1.58
Simian immunodeficiency virus infection of monkeys as a model system for the study of AIDS pathogenesis, treatment, and prevention. Adv Pharmacol (2000) 1.57
Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J Natl Cancer Inst (2001) 1.55
An antineuronal antibody cross-reacting with erythrocytes and lymphocytes in systemic lupus erythematosus. Arthritis Rheum (1979) 1.54
Risk of breast cancer in women with benign breast disease. J Natl Cancer Inst (1980) 1.54
Doxazosin for the management of hypertension: implications of the findings of the ALLHAT trial. Am J Hypertens (2001) 1.54
The impact of smoking status, disease stage, and index tumor site on second primary tumor incidence and tumor recurrence in the head and neck retinoid chemoprevention trial. Cancer Epidemiol Biomarkers Prev (2001) 1.50
Spinal extradural arachnoid pouches. Report of two cases. J Neurosurg (1982) 1.49
Mechanical strain-induced extracellular matrix production by human vascular smooth muscle cells: role of TGF-beta(1). Hypertension (2000) 1.49
Determination of plasma viral load in HIV-1 infection by quantitative competitive polymerase chain reaction. AIDS (1993) 1.48
Stimulation of glycoprotein gp120 dissociation from the envelope glycoprotein complex of human immunodeficiency virus type 1 by soluble CD4 and CD4 peptide derivatives: implications for the role of the complementarity-determining region 3-like region in membrane fusion. Proc Natl Acad Sci U S A (1991) 1.48
Intrinsic susceptibility of rhesus macaque peripheral CD4(+) T cells to simian immunodeficiency virus in vitro is predictive of in vivo viral replication. J Virol (2000) 1.47
Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus. J Virol (2000) 1.47
Administration of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) for prevention of perinatal simian immunodeficiency virus infection in rhesus macaques. AIDS Res Hum Retroviruses (1998) 1.46
In vivo attenuation of simian immunodeficiency virus by disruption of a tyrosine-dependent sorting signal in the envelope glycoprotein cytoplasmic tail. J Virol (2001) 1.45
The safety and pharmacokinetics of GLQ223 in subjects with AIDS and AIDS-related complex: a phase I study. AIDS (1990) 1.44
Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates. Adv Exp Med Biol (1996) 1.44
Nef enhances human immunodeficiency virus replication and responsiveness to interleukin-2 in human lymphoid tissue ex vivo. J Virol (1999) 1.43
Clinical evaluation of branched DNA signal amplification for quantifying HIV type 1 in human plasma. AIDS Res Hum Retroviruses (1995) 1.42
Cerebrospinal fluid pressure changes in response to coughing. Brain (1976) 1.42
Biological embedding of stress through inflammation processes in childhood. Mol Psychiatry (2010) 1.42
Non-cytolytic CD8 T-cell anti-HIV responses in primary HIV-1 infection. Lancet (1994) 1.40
PET, PTCA, and economic priorities. Clin Cardiol (1990) 1.40